Pfizer extends tender offer for King

NEW YORK — Pfizer again has extended the expiration date on its tender offer to buy Bristol, Tenn.-based King Pharmaceuticals to Jan. 28, the drug maker said Friday.

Pfizer announced in October that it would buy King for $3.6 billion, or $14.25 per share. King manufactures branded prescription drugs, including several painkillers.

In December, Pfizer, the world’s largest drug maker, had extended its offer for King until Friday.

Login or Register to post a comment.